Morgan Stanley raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $94 from $90 and keeps an Overweight rating on the shares after “another strong quarter” in Q3, highlighted by Tryngolza in FCS outperforming again and driving a third guidance raise for the year. The firm expects detailed SHTG data at the upcoming AHA meeting on November 8 to “further strengthen the profile,” the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $99 from $59 at TD Cowen
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Future Catalysts Support Buy Rating
- Ionis Pharmaceuticals price target raised to $95 from $80 at Barclays
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q3 2025 Growth